OBJECTIVE: We previously reported in healthy volunteers that a cantaloupe melon extract chemically combined with wheat gliadin (melon extract/gliadin) and containing SOD, catalase and residual glutathione peroxidase (GPx), protected against DNA strand-break damage induced by hyperbaric oxygen (HBO), a well-established model of DNA damage resulting from oxidative stress. Aortic cross-clamping is a typical example of ischemia/reperfusion injury-related oxidative stress, and therefore we investigated whether this melon extract/gliadin would also reduce DNA damage after aortic cross-clamping and reperfusion. DESIGN: Prospective, randomized, controlled experimental study. SETTING: Animal laboratory. PATIENTS AND PARTICIPANTS: 18 anesthetized, mechanically ventilated and instrumented pigs. INTERVENTIONS: After 14 days of oral administration of 1250 mg of the melon extract/gliadin (n=9) or vehicle (n=9), animals underwent 30 min of thoracic aortic cross-clamping and 4 h of reperfusion. MEASUREMENTS AND RESULTS: Before clamping, immediately before declamping, and at 2 and 4 h of reperfusion, we measured blood isoprostane (immunoassay) and malondialdehyde concentrations (fluorimetric thiobarbituric acid test), SOD, catalase and GPx activities (spectrophotometric kits), NO formation (nitrate+nitrite; chemoluminescence), DNA damage in whole blood samples and isolated lymphocytes exposed to hyperbaric oxygen (comet assay). Organ function was also evaluated. Kidney and spinal cord specimen were analysed for apoptosis (TUNEL assay). The melon extract/gliadin blunted the DNA damage, reduced spinal cord apoptosis and attenuated NO release, however, without any effect on lipid peroxidation and organ function. CONCLUSIONS: Pre-treatment with the oral melon extract/gliadin may be a therapeutic option to reduce oxidative cell injury affiliated with aortic cross-clamping.
OBJECTIVE: We previously reported in healthy volunteers that a cantaloupe melon extract chemically combined with wheat gliadin (melon extract/gliadin) and containing SOD, catalase and residual glutathione peroxidase (GPx), protected against DNA strand-break damage induced by hyperbaric oxygen (HBO), a well-established model of DNA damage resulting from oxidative stress. Aortic cross-clamping is a typical example of ischemia/reperfusion injury-related oxidative stress, and therefore we investigated whether this melon extract/gliadin would also reduce DNA damage after aortic cross-clamping and reperfusion. DESIGN: Prospective, randomized, controlled experimental study. SETTING: Animal laboratory. PATIENTS AND PARTICIPANTS: 18 anesthetized, mechanically ventilated and instrumented pigs. INTERVENTIONS: After 14 days of oral administration of 1250 mg of the melon extract/gliadin (n=9) or vehicle (n=9), animals underwent 30 min of thoracic aortic cross-clamping and 4 h of reperfusion. MEASUREMENTS AND RESULTS: Before clamping, immediately before declamping, and at 2 and 4 h of reperfusion, we measured blood isoprostane (immunoassay) and malondialdehyde concentrations (fluorimetric thiobarbituric acid test), SOD, catalase and GPx activities (spectrophotometric kits), NO formation (nitrate+nitrite; chemoluminescence), DNA damage in whole blood samples and isolated lymphocytes exposed to hyperbaric oxygen (comet assay). Organ function was also evaluated. Kidney and spinal cord specimen were analysed for apoptosis (TUNEL assay). The melon extract/gliadin blunted the DNA damage, reduced spinal cord apoptosis and attenuated NO release, however, without any effect on lipid peroxidation and organ function. CONCLUSIONS: Pre-treatment with the oral melon extract/gliadin may be a therapeutic option to reduce oxidative cell injury affiliated with aortic cross-clamping.
Authors: P B Dimakakos; T Kotsis; A Kondi-Pafiti; K Katsenis; A Doufas; K Chondros; E Kouskouni Journal: J Cardiovasc Surg (Torino) Date: 2002-02 Impact factor: 1.888
Authors: S R Kearns; C J Kelly; M Barry; H Abdih; C Condron; A Leahy; D Bouchier-Hayes Journal: Eur J Vasc Endovasc Surg Date: 1999-06 Impact factor: 7.069
Authors: S Loft; P N Larsen; A Rasmussen; A Fischer-Nielsen; S Bondesen; P Kirkegaard; L S Rasmussen; E Ejlersen; K Tornøe; R Bergholdt Journal: Transplantation Date: 1995-01-15 Impact factor: 4.939
Authors: Marek Nalos; Pierre Asfar; Carole Ichai; Peter Radermacher; Xavier Maurice Leverve; Gebhard Fröba Journal: Intensive Care Med Date: 2002-11-02 Impact factor: 17.440
Authors: M G Clemente; S De Virgiliis; J S Kang; R Macatagney; M P Musu; M R Di Pierro; S Drago; M Congia; A Fasano Journal: Gut Date: 2003-02 Impact factor: 23.059
Authors: Massimo Antonelli; Elie Azoulay; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; Daniel De Backer; François Lemaire; Herwig Gerlach; Johan Groeneveld; Goran Hedenstierna; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Philipp Metnitz; Jerme Pugin; Jan Wernerman; Haibo Zhang Journal: Intensive Care Med Date: 2008-01-31 Impact factor: 17.440
Authors: Florian Simon; Angelika Scheuerle; Michael Gröger; Brigitta Vcelar; Oscar McCook; Peter Möller; Michael Georgieff; Enrico Calzia; Peter Radermacher; Hubert Schelzig Journal: Intensive Care Med Date: 2011-07-16 Impact factor: 17.440
Authors: Christian Maier; Angelika Scheuerle; Balázs Hauser; Hubert Schelzig; Csaba Szabó; Peter Radermacher; Jochen Kick Journal: Intensive Care Med Date: 2007-03-15 Impact factor: 17.440
Authors: Andre Bredthauer; Karla Lehle; Angelika Scheuerle; Hubert Schelzig; Oscar McCook; Peter Radermacher; Csaba Szabo; Martin Wepler; Florian Simon Journal: Intensive Care Med Exp Date: 2018-10-24